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Abstract
 
Neurotrophins (nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF],
neurotrophin [NT]-3, and NT-4) have been observed in elevated concentrations in allergic
diseases. Neurotrophin levels are up-regulated endobronchially after allergen challenge. This
coincides with an influx of activated eosinophils into the bronchial lumen. These eosinophils
have an increased viability and CD69 expression 18 h after segmental allergen provocation
(SAP) which is not present in peripheral blood. To investigate whether these observations are
related we studied the influence of neurotrophins on eosinophil function in allergic asthma.
Incubation with NGF, BDNF, NT-3, or NT-4 caused a significant increase in the viability
and CD69 expression of isolated eosinophils from bronchoalveolar lavage fluid (BALF) but not
from peripheral blood, suggesting a unique sensitivity of endobronchial eosinophils to neu-
rotrophins. To elucidate the underlying mechanisms expression of the neurotrophin receptors
p75NTR, trkA, trkB, and trkC on eosinophils was analyzed by RT-PCR and immunocytol-
ogy. After SAP expression of all neurotrophin receptors was markedly elevated on eosinophils
from BALF. Our findings suggest that neurotrophin-mediated activation of bronchial eosino-
phils might play a role in the regulation of eosinophilic inflammation in allergic asthma.
Key words: allergic asthma • eosinophils • neurotrophins • neurotrophin receptors • segmental 
allergen provocation
 
Introduction
 
Bronchial asthma is a chronic inflammatory disorder with
an increased responsiveness of the airways to nonspecific
stimuli. Inhalation of allergen causes a biphasic, reversible
airflow obstruction referred to as the early and late phase
response. During the late phase response an infiltration of
the airways with activated T lymphocytes and eosinophils
has been recognized and this has been associated with an
increase in bronchial hyperreactivity (BHR)
 
*
 
 (1–4).
Neurotrophins such as nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), neurotrophin
(NT)-3, and NT-4 have recently gained widespread at-
tention in allergic diseases. Initial evidence came from in-
vestigations in humans where NGF concentrations in the
peripheral blood correlated with the severity of allergic
manifestations and highest levels of NGF were measured in
patients with asthma. They were also correlated with other
atopy-related parameters such as eosinophil cationic protein
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Abbreviations used in this paper:
 
 BALF, bronchoalveolar lavage fluid;
BDNF, brain-derived neurotrophic factor; BHR, bronchial hyperrespon-
siveness; FEV
 
1
 
, forced expiratory volume in one second; NGF, nerve
growth factor; NT, neurotrophin; PI, propidium-iodide; p75NTR, low
affinity pan-neurotrophin receptor; rSMF, relative SMF; SAP, segmental
allergen provocation; SMF, specific mean fluorescence; trk, tyrosine ki-
nase, high affinity neurotrophin receptor.T
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(ECP) and IgE Ab levels (5). Further investigations found
increased concentrations of NGF and NT-3 in bronchoal-
veolar lavage fluid (BALF) in patients with asthma com-
pared with nonatopic normal controls (6). Recently, we
were able to report that segmental allergen provocation
(SAP) induces an increase in the concentrations of NGF,
BDNF, and NT-3 in BALF suggesting that neurotrophins
are produced locally following allergen provocation (7).
Possible sources of neurotrophins in allergic inflammation
are neurons, neuron-associated cells (8–10) and immune
cells such as macrophages, mast cells, T cells, B cells, epi-
thelial cells, and eosinophils (11–18).
It has been speculated that the release of neurotrophins
in atopic diseases after allergen challenge might link inflam-
matory changes observed in asthma with the increase in
bronchial hyperresponsiveness. In an animal model of
asthma NGF can mimic several key features of asthma by
augmenting BHR and allergic inflammation (15), probably
due to neurotrophin-induced up-regulation of neuropep-
tide production in sensory neurons (19, 20). Neurotrophins
not only affect nerve cells but can also interfere with allergy
related immune cell functions such as mast-cell degranula-
tion, Th2 cytokine synthesis, Ab production from B cells,
and eosinophil survival (15, 21–23).
The neurotrophin effects are mediated by the low affin-
ity (K
 
d
 
 10
 
 
 
9
 
) pan-neurotrophin receptor p75NTR to
which all members of the neurotrophin family bind with
similar affinity (24, 25), and/or the tyrosine protein kinase
receptors of the tyrosine kinase, high affinity neurotrophin
receptor (trk) family to which neurotrophins bind with
high affinity (K
 
d
 
 10
 
 
 
11
 
). TrkA has been identified as the
preferred receptor for NGF (26, 27) and trkB has been re-
ported to exert the effects of both BDNF and NT-4 (28,
29). For NT-3, trkC plays a central role in cellular signaling
(30). Neurotrophin receptors are expressed on several im-
mune cells including mast cells, T cells, B cells, and macro-
phages (14, 21, 31–37). Previous investigations about
neurotrophin receptor expression in the bone marrow in-
dicated that expression on eosinophils depended on the
stage of differentiation. Polymorphnuclear eosinophils in
human bone marrow preparations showed immunoreactiv-
ity for trkB kinase, the truncated trkC and the trkC kinase
(38). In contrast, peripheral blood granulocytes do not ex-
press mRNA for neurotrophin receptors (39).
Based on the pleiotrophic actions of neurotrophins on
other cells of the inflammatory cascade in allergic asthma we
hypothesized that neurotrophins might have direct effects
on eosinophil function in human allergic inflammation. To
address this question neurotrophin receptor expression on
eosinophils was investigated before and after segmental al-
lergen challenge in peripheral blood and BALF cells from
patients with allergic asthma and eosinophil function and
survival in response to neurotrophins was tested in vitro.
 
Materials and Methods
 
Subjects.
 
Eight nonsmoking, allergic subjects (3 female and 5
male) with mild asthma (mean age 27.4 
 
 
 
 1.1 yr, range 23–33)
 
and a mean FEV
 
1 
 
(forced expiratory volume in one second) of
99.5 
 
 
 
 3.9% (84.2–117.0%) of predicted (40) were included in
the study. Mean total IgE levels were 318.4 
 
 
 
 106.1 kg units per
liter (kU/l; range 71.8–986.0 kU/l). All patients had positive skin
prick test reactions (Allergopharma) and elevated specific IgE
concentrations (36.5 
 
 
 
 12.7 kU/l; Kabi, Pharmacia CAP Sys-
tem
 
®
 
) to at least one common aeroallergen. All subjects had a his-
tory of intermittent wheeze, chest tightness, cough, and sputum
production and reversible bronchoconstriction after inhalation of
allergens (Table I). There was no evidence suggesting respiratory
tract infections before or at the time of the segmental allergen
challenge. All subjects received inhaled 
 
 
 
2
 
-agonist therapy as
needed. Inhaled corticosteroids were withdrawn at least 7 d be-
fore the study. All subjects gave informed consent. The study
protocol was approved by the Ethics Committee of the Univer-
sity of Freiburg.
The healthy donors had no history of atopic diseases, normal
pulmonary function tests, IgE levels within the normal range, and
had not been taking any medication 4 wk before the study. All
patients and normal controls were nonsmokers.
 
Inhaled Allergen Provocation.
 
The inhaled allergen provoca-
tion was performed as described previously (41). The individual
provocative dose of allergen (rye pollen, birch pollen, or house
dust mite allergen) that caused a 20% fall in FEV
 
1
 
 (PD
 
20
 
) was ex-
trapolated for each patient according to the cumulative dose of al-
lergen inhaled until a drop of the FEV
 
1
 
 of 
 
 
 
20% was recorded. A
10-fold higher dose of allergen was then used for the subsequent
segmental allergen provocation. Inhaled and segmental allergen
provocations were at least 3 wk apart.
 
Segmental Allergen Provocation.
 
Bronchoscopy and SAP were
performed as described previously (41) using an Olympus
BF 1T30 (Olympus Optical Co.) following local anesthesia
(Novesine
 
®
 
; Wander). Saline (2.5 ml) was instilled into one seg-
ment of the lower left lobe (usually B8) and into the inferior lin-
gular bronchus (B5 left; control). 10 min later, the lower lobe
segment was lavaged with 100 ml prewarmed saline. Two ali-
quots of allergen extract were diluted in 2.5 ml of saline and in-
stilled into two segments of the right lung (B8 and B5). After an-
other 10 min after endoscopic allergen deposition, the lower lobe
segment was lavaged with 100 ml of normal, prewarmed saline in
aliquots of 20 ml. Patients were rebronchoscoped after 18 h at
which time the lingular and middle lobe bronchus were again la-
vaged with 100 ml of saline as described above.
 
Analysis of Bronchoalveolar Lavage Leukocytes.
 
BALF samples
were filtered through a two layer sterile gauze into sterile plastic
vials, centrifuged at 4
 
 
 
C and 500 
 
g
 
 for 10 min. After removing the
supernatants, cytospins were made and cells stained with May
Grünwald Giemsa solution. Differential cell counts were per-
formed on all nucleated cells and results expressed as total number
of cells per ml of recovered fluid.
 
Purification of Eosinophils.
 
Eosinophils were purified as de-
scribed (42). Peripheral blood eosinophils were obtained from 27
ml EDTA blood of asthmatics 10 min before and 18 h after SAP
or from 54 ml EDTA blood of healthy donors. Blood was di-
luted 1:1 with PBS and 20 ml aliquots were overlayered onto 20
ml of isotonic Percoll
 
®
 
 solution (density 1.8 g/ml; Amersham
Biosciences) and centrifuged for 30 min at 1,000 
 
g
 
 at 4
 
 
 
C. After
centrifugation, the supernatant was removed and the mononu-
clear cells at the interface were aspirated. Erythrocytes and plate-
lets were removed by hypotonic lysis (0.2% NaCl for 30 s). Eo-
sinophils were separated by negative selection of neutrophils,
using immunomagnetic beads. The pellet was resuspended in 1
ml PBS (Dulbecco) containing 2% heat inactivated FCS (PBS/T
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2% FCS; GIBCO BRL) and 5 
 
 
 
l of CD16 microbeads (Miltenyi
Biotech) per 10
 
7
 
 neutrophils were added for 30 min at 4
 
 
 
C with
occasional mixing. The cell suspension was added on top of the
separation column which was placed in a magnetic field (Vario-
MACS
 
®
 
; Miltenyi Biotech). Eosinophils were eluted with ice
cold PBS/2% FCS. After separation, cells were washed in PBS/
2% FCS and then diluted in culture medium (RPMI 1640 with
10% heat inactivated FCS, 2 mM 
 
l
 
-glutamine, 100 IU/ml peni-
cillin, and 100 
 
 
 
g/ml streptomycin [Seromed; Biochrom]). The
purity of eosinophils was consistently 
 
 
 
98%, as assessed by
Kimura staining.
The procedure of isolating eosinophils from BALF was per-
formed in a similar fashion. BALF cells were diluted in 5 ml cul-
ture medium and overlayered onto 5 ml Percoll
 
®
 
 solution. After
washing the cells twice, differential cell counts were performed
and eosinophils were separated from neutrophils as described
above. The purity of BALF eosinophils was also consistently
 
 
 
98%, as assessed by Kimura staining.
 
Cell Culture.
 
Eosinophils (0.5 
 
 
 
 10
 
5
 
 cells/ml) were cultured
at 37
 
 
 
C in a humidified atmosphere with 5% CO
 
2
 
 either in the
culture medium alone or in the presence of 0.05, 0.5, 5, or 50
ng/ml 
 
r
 
human 
 
 
 
-NGF (BioConcept), BDNF (Biosource Inter-
national) 
 
r
 
human NT-3, 
 
r
 
human NT-4 (both BioConcept), or 10
ng/ml 
 
r
 
human IL-5 (Genzyme). All neurotrophins and the IL-5
contained less than 0.1 ng endotoxin per 
 
 
 
g. Before immunoflu-
orescence labeling, cells were washed twice in PBS/2% FCS.
 
Flow Cytometric Analysis of CD69 Cell Surface Expression.
 
Flow cytometric analysis of CD69 cell surface expression was
performed as described previously (42). 20 
 
 
 
l of cell suspensions
(5 
 
 
 
 10
 
4
 
 cells) were incubated in the presence of saturating con-
centrations of PE conjugated mouse anti–human CD69 mAbs
(Becton Dickinson) or PE-conjugated IgG
 
1
 
 (DakoCytomation),
respectively, for 30 min on ice. Cells were then washed once in
PBS/2% FCS and resuspended in 100 
 
 
 
l of a propidium-iodide
solution (PI; 0.5 
 
 
 
g/ml dissolved in PBS; Sigma-Aldrich). Flow
cytometry was performed on at least 5,000 cells from each sam-
ple with a FACScan™ Flow Cytometer (Becton Dickinson). To
include only viable cells in the analysis, PI positive, nonviable
cells were excluded by appropriate gating in a separate fluores-
cence channel. Nonspecific fluorescence was determined by in-
cubating cells with mouse IgG of the same isotype but with irrel-
evant Ag specificity (IgG
 
1
 
). The specific mean fluorescence
(SMF) for each population was determined by subtracting the
nonspecific mean fluorescence (NMF) of the isotype control. To
correct for variations in cell autofluorescence between patients
and different cell populations, the relative SMF (rSMF) was cal-
culated, which is the ratio of the SMF emitted by the bound spe-
cific mAbs and that of the NMF of the corresponding isotype
control (43).
 
Survival Assay.
 
Survival of cultured eosinophils was assessed in
a PI assay. 5 
 
 
 
 10
 
4
 
 cells were washed once in PBS and resus-
pended in 100 
 
 
 
l of a PI solution. Flow cytometry was performed
on at least 5,000 cells from each sample. The data were aquired
and analyzed by the CELLQuest™ software (Becton Dickinson).
 
Neutralization of Neurotrophin-induced Survival and CD69 Surface
Expression
 
To verify that the observed effects were mediated by
the different neurotrophins, BALF eosinophils were incubated
with either 50 ng/ml NGF, BDNF, NT-3, or NT-4 alone or in
combination with either a monoclonal mouse IgG
 
1
 
 (20 
 
 
 
g/ml)
or a mouse NGF, BDNF, NT-3, or NT-4 mAb (each 20 
 
 
 
g/ml,
IgG
 
1
 
; R&D Systems). Viability and CD69 expression of eosino-
phils were measured after 10 d or after 4 h, respectively, as de-
scribed above.
 
RT-PCR.
 
Neurotrophin receptor mRNA expression of pu-
rified eosinophils obtained 18 h after SAP from peripheral blood
or BALF fluid of patients with asthma, respectively, was exam-
ined. mRNA was extracted from total cellular RNA using com-
mercially available (m)RNA-isolation kits (RNeasy Mini Kit and
Oligotex mRNA Isolation Kit, both QIAGEN). Reverse tran-
scription was performed with 7.5 ng of mRNA from each sample
in a 20 
 
 
 
l reaction for 60 min at 37
 
 
 
C followed by 5 min at 95
 
 
 
C
according to the manufacturer’s recommendation (Sensiscript
RT-Kit; QIAGEN). As control, 7.5 ng mRNA of each sample
was treated according to the same protocol with addition of water
instead of the Reverse Transcriptase. Real time PCR was per-
formed on the Light Cycler Instrument (Roche Molecular Bio-
chemicals) using the DNA-binding dye SYBR green (Light Cy-
cler - Fast Start DNA Master SYBR Green I; Roche Molecular
Biochemicals). PCR reaction mix contained 2 
 
 
 
l PCR master
mix supplemented with 2.5 mM MgCl
 
2
 
 (magnesium chloride),
custom synthesized primers (MWG Biotech), and 2 
 
 
 
l of cDNA
or control RNA, respectively, in a final volume of 20 
 
 
 
l. The
specific primers used for PCR were 
 
 
 
-actin (sense: 5
 
 
 
-TCC-
CTGGAGAAGAGCTACGA-3
 
 
 
, antisense: 5
 
 
 
-AGCACTGT-
GTTGGCGTACAG-3
 
 
 
; GenBank/EMBL/DDBJ accession no.
BC013380; expected product length 194 bp), p75NTR (sense:
5
 
 
 
-CCTACGGCTACTACCAGGATG-3
 
 
 
; antisense: 5
 
 
 
-TGG-
CCTCGTCGGAATACG-3
 
 
 
; GenBank/EMBL/DDBJ acces-
sion no. M14764; calculated product length: 147 bp) (44), trkA
(sense: 5
 
 
 
-AATGCCTCGGTGGATGTG-3
 
 
 
; antisense: 5
 
 
 
-
AGCGTGTAGTTGCCGTTGTT-3
 
 
 
; GenBank/EMBL/DDBJ
accession no. NM_002529; expected product length: 479 bp),
trkB (sense: 5
 
 
 
-CCCACTCACATGAACAATGG-3
 
 
 
; antisense:
5
 
 
 
-TCAGTGACGTCTGTGGAAGG-3
 
 
 
; GenBank/EMBL/
DDBJ accession no. NM_006180; calculated product length: 221
bp), and trkC (sense: 5
 
 
 
-AAGCGAGAACTGGGTGAGG-3
 
 
 
;
antisense: 5
 
 
 
-ATGTGGAGCATTTGGGAGAG-3
 
 
 
, GenBank/
EMBL/DDBJ accession no. S76475; expected product length:
356 bp). After an initial denaturation step at 95
 
 
 
C for 10 min the
PCR reaction was performed with an annealing temperature of
60
 
 
 
C for 10 s, followed by an extension phase at 72
 
 
 
C for 9 s, and
a denaturation cycle at 95
 
 
 
C for 1 s. At the end of each extension
phase, fluorescence was observed at 72
 
 
 
C. The PCR reaction was
completed after 45 cycles. The melting point analysis was per-
formed by heating the amplicon from 65 to 95
 
 
 
C and revealed
the characteristic melting point for each product. After cooling
down to 40
 
 
 
C the product was extracted from the capillary. 10 
 
 
 
l
of each reaction were run onto a 1.5% agarose gel and visualized
by staining with ethidium bromide. PCR products were com-
mercially sequenced (GATC Biotech).
 
Immunocytochemistry.
 
To examine neurotrophin receptor pro-
tein expression on eosinophils, immunocytochemistry was per-
formed on acetone fixed cytospin preparations from BALF and
purified blood eosinophils after SAP with the EnVision™ Alka-
line Phosphatase System for mouse and rabbit Abs/Fast Red (Da-
koCytomation) according to the manufacturer’s instructions. Af-
ter washing in aqua bidest and in TBS (Tris-phosphate buffered
saline; 0.05 M Tris, 0.9% NaCl, pH 7.6), cytospin preparations
were blocked for 2 h with 2% goat serum (DakoCytomation) in
TBS. Primary Abs diluted in TBS were added in optimized con-
centrations (up to 10 
 
 
 
g/ml) and incubated overnight at 4 C. Ir-
relevant isotypes from the same species served as negative con-
trols. In one experiment, the 10-fold concentration of each
isotype control antibody was used to ascertain the specificity of
the binding of the antibodies used. After washing in TBS (3   5
min), EnVision™ anti–rabbit/mouse was added for 30 min.T
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Three washes with TBS were followed by counterstaining with
the Fast Red solution (one tablet and three drops levamisole dis-
solved in 3 ml of buffer). All cytospins were microscopically ex-
amined and photodocumented with the help of the photomicro-
graphic system SC 35 (Olympus).
Antibodies. A monoclonal anti–human nerve growth factor
receptor (p75NTR) antibody, clone NGFR5 (NeoMarkers) di-
rected against the extracellular domain of the receptor, was used to
study surface and cytoplasmatically localized p75NTR immunore-
activity. The polyclonal rabbit antibodies TrkA (763), TrkB (794)
(all Santa Cruz Biotechnology, Inc.), TrkB23–36 (Chemicon), TrkB
(H-181), and TrkC (798) (both from Santa Cruz Biotechnology,
Inc.) and the monoclonal mouse antibodies TrkA, clone H-10
(Cymbus Biotechnology LTD, distributed by Chemicon) and
TrkC, clone 75219 (R&D Systems), were used to study Trk fam-
ily receptor expression. TrkA (763) reacts with a carboxy terminal
epitope of human TrkA (amino acids 763–777). TrkB (794) and
TrkC (798) with carboxy terminal peptides (794–808 and 798–
812 residues, respectively) of gp145TrkB or gp145TrkC proteins.
TrkB23–26 is raised against a synthetic peptide from TrkB (amino
acids 23–36) and TrkB (H-181) against a recombinant protein
corresponding to amino acids 160–340 mapping within the extra-
cellular domain of TrkB of human origin. Mouse IgG1 was used as
isotype-control for the anti-p75NTR antibody, mouse IgG2a for
the monoclonal TrkA antibody, mouse IgG2b for the monoclonal
trkC antibody (both from DakoCytomation), and rabbit IgG
(R&D Systems) for the polyclonal antibodies.
Statistical Analysis. Results are expressed as arithmetic
mean   SEM. Statistical evaluation was performed with Sigma-
Stat® for Windows. Differences between two normal variable
groups were analyzed using the unpaired Student t test. Differ-
ences before and after SAP in normally distributed groups were
analyzed using the paired t test or the signed rank test for non-
parametric samples, respectively. Differences with P values  0.05
were considered statistically significant.
Results
Eosinophils in Peripheral Blood and BALF after Segmental
Allergen Provocation. A marked increase in the number of
eosinophils was observed in the allergen challenged seg-
ment 18 h after allergen provocation which was signifi-
cantly higher (P   0.05) compared with the segment la-
vaged 10 min after allergen challenge or 10 min and 18 h
after saline challenge (Table II).
In addition, there was a significant increase in the num-
ber of peripheral blood eosinophils 18 h after allergen in-
stillation compared with the number of eosinophils 10 min
before SAP (P   0.05; Table III).
Table I. Patient Characteristics
Sex Age
FEV1 baseline
(liter)
FEV1
% pred
IgE 
(kU/l) Allergen
Specific
IgE 
(kU/l)
Allergen Dose
(AU) Medication
f 33 3.1 98.7 72 birch 6.2 160  
f 27 2.9 84.2 83 birch 16.0 3  , ICS
m 29 4.1 91.2 214 D. pt. 35.0 6  
m 29 4.5 96.5 242 birch 93.5 88  , ICS
m 26 3.7 97.6 161 birch 59.2 526  
m 27 5.7 114.4 986 rye >100 98  
m 23 5.8 117.0 306 D. pt. 33.9 4,700  
f 25 3.1 87.0 483 D. pt. 99.5 35  
Birch, birch pollen; D. pt., Dermatophagoides pteronyssinus; rye, rye pollen;  ,  2-agonists; ICS, inhaled corticosteroids. 
Table II. Cellular Composition in BALF after SAP (Cells   103/ml; Mean   SEM)
 Recovery
Macrophages
( 103/ml)
Lymphocytes
( 103/ml)
Eosinophils
( 103/ml)
Neutrophils
( 103/ ml)
10 min saline 55   4 ml 297.8   137.2 28.2   8.2 1.4   0.6 0.3   0.2
10 min allergen 52   5 ml 286.7   130.9 14.2   2.5 1.5   0.4 1.1   0.5
18 h saline 63   5 ml 433.1   171.3 34.1   3.8 1.3   0.3 5.1   1.5
18 h allergen 54   3 ml 357.9   124.2 87.6   18.6* 129.6   35.0* 109.1   41.8*
10 min saline: control segment lavaged 10 min after instillation of 2.5 ml normal saline; 10 min allergen: allergen challenged segment lavaged 10 min
after instillation of allergen with 10  of the inhaled provocation dose causing a 20% fall in forced expiratory volume in one second (PD20); 18 h
saline: control segment lavaged 18 h after instillation of 2.5 ml normal saline, 18 h allergen: allergen challenged segment lavaged 18 h after instillation
of allergen 10  PD20. Cell numbers are given in absolute numbers; n   8; *P   0.05 compared to 18 h saline.T
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Due to the limited total number of cells recovered, it
was possible to separate sufficient quantities of eosinophils
from both peripheral blood 10 min before and 18 h after
SAP as well as from allergen challenged lung segments 18 h
after allergen treatment in only four patients for further in
vitro experiments. In contrast, the purification of eosino-
phils from the BALF of the saline challenged lung segments
after 10 min and 18 h as well as those of the allergen treated
segment after 10 min did not yield sufficient numbers of
eosinophils to allow cell culture and further analysis.
CD69 Expression on Eosinophils after SAP. To deter-
mine the activation state of eosinophils, the expression of
the activation marker CD69 was measured. CD69 on periph-
eral blood eosinophils of healthy donors (n   8) was 0.1  
0.0 rSMF and showed no difference to that of patients with
asthma 10 min before SAP. There was a slight increase 18 h
after allergen challenge (0.3   0.1 rSMF) but this difference
did not reach statistical significance. In contrast, eosinophils
obtained from BALF 18 h after SAP showed a markedly in-
creased CD69 surface expression (4.9   0.3 rSMF; P  
0.05 to blood eosinophils taken 18 h after SAP).
CD69 Expression of BALF and Peripheral Blood Eosinophils
after Stimulation with Neurotrophins. To assess whether
neurotrophins can induce CD69 expression, purified eo-
sinophils obtained from peripheral blood of healthy donors
and from asthmatics 10 min before and 18 h after SAP were
cultured with NGF, BDNF, NT-3, or NT-4 (50 ng/ml
each) for 4 h. No significant effect on the activation of the
cells as determined by CD69 expression was detected (n  
8 [healthy controls] or n   4 [asthmatics], respectively; Fig.
Table III. Cellular Composition in Venous Blood 10 min before and 18 h after SAP (Cells   103/ml; Mean   SEM)
Cells   103/ml Monocytes Lymphocytes Eosinophils Neutrophils Basophils
10 min before SAP 488.0   108.4 1,945.9   112.4 248.4   62.0 3,949.2   552.7 41.7   11.5
18 h after SAP 549.5   76.7 1,958.3   242.7 378.6   82.0* 5,064.2   742.4 46.7   11.3
10 min before SAP: venous blood taken 10 min before SAP, 18 h after SAP: venous blood taken 18 h after SAP; n   8; *P   0.05 compared to 10 
min before SAP.
Figure 1. Comparison of the
CD69 expression of peripheral
blood eosinophils with BALF eo-
sinophils after SAP. Purified eosino-
phils (0.5   105/ml) of peripheral
blood obtained from healthy donors
or from asthmatics 10 min before
and 18 h after SAP and BALF eo-
sinophils from asthmatics obtained
18 h after SAP were incubated with
50 ng/ml NGF, BDNF, NT-3, or
NT-4, respectively, or with cell cul-
ture medium alone (control). After
4 h, the CD69 expression was mea-
sured by flow cytometry. The figures
show representative histograms of at
least four independent experiments.T
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1), whereas stimulation with IL-5 caused a significant in-
crease (P   0.05) in CD69 (healthy donors: 2.1   0.3
rSMF, asthmatics 10 min before SAP: 2.3   0.4 rSMF,
asthmatics 18 h after SAP: 1.9   0.3 rSMF).
Stimulation of BALF eosinophils both with NGF,
BDNF, NT-3 or NT-4, respectively, caused a significant
increase in CD69 surface expression (NGF: 5.8   0.3
rSMF, BDNF: 6.4   0.5 rSMF, NT-3: 5.7   0.2 rSMF,
NT-4: 6.8   0.7 rSMF; n   4, each P   0.05 compared
with control [4.9   0.3 rSMF]; Fig. 1). In BALF eosino-
phils 50 ng/ml of neurotrophins caused a similar degree of
eosinophil activation (as measured by CD69 expression) as
did 10 ng/ml IL-5 (5.8   0.3 rSMF).
The neurotrophin-mediated increase of CD69 expres-
sion was dose-dependent and comparable results were
found for NGF, BDNF, NT-3, and NT-4 (Fig. 2).
Ex Vivo Viability of Eosinophils Obtained from Peripheral
Blood and BALF after SAP. The viability of eosinophils
was examined by PI exclusion. The percentage of viable
eosinophils from BALF was significantly increased com-
pared with peripheral blood cells from healthy controls and
from asthmatics 10 min before and 18 h after SAP (Fig. 3).
After 3 d in culture, the viability of BALF eosinophils was
significantly increased (66.4   12.2%, P   0.05, n   4)
compared with that from peripheral blood eosinophils iso-
lated 10 min before (22.1   11.1%) and 18 h (37.0  
6.2%) after SAP and those from blood of healthy donors
(11.3   3.4%, n   6). In contrast, the differences between
the percentage of viable peripheral blood eosinophils from
patients with asthma 10 min before and 18 h after SAP and
healthy controls did not reach statistical significance.
Ex Vivo Viability of Peripheral Blood and BALF Eosinophils
after Stimulation with NGF, BDNF, NT-3, or NT-4. The
effect of neurotrophins on eosinophil survival was assessed
after incubation of peripheral blood eosinophils from
healthy donors with 50 ng/ml NGF, BDNF, NT-3, or
NT-4. Neurotrophins did not change viability which was
13.5   4.8% (control) after 3 d in culture (n   6; Fig. 4).
Because of the observed differences in the survival of
eosinophils obtained from peripheral blood of healthy sub-
jects, and from asthmatics before and after SAP compared
with BALF eosinophils from patients with asthma, viability
of peripheral blood eosinophils from asthmatics was also as-
sessed after 5 and 7 d in culture, whereas survival of BALF
eosinophils was also measured after 10 and 14 d. After 7 d
in culture, only 2.6   0.8% of the peripheral blood eosino-
phils obtained from asthmatics before SAP were still viable.
Neither NGF, BDNF, NT-3, nor NT-4 had any signifi-
cant influence on cell viability (Fig. 4). After stimulation of
peripheral blood eosinophils obtained 18 h after SAP with
neurotrophins, comparable results were observed (Fig. 4).
In contrast, incubation of BALF eosinophils for 14 d with
either 50 ng/ml NGF, BDNF, NT-3, or NT-4 increased
the percentage of viable, PI negative cells significantly
(controls: 5.8   3.8%, NGF: 45.9   8.9%, BDNF: 47.9  
13.0%, NT-3: 49.3   18.0%, NT-4: 42.6   14.8%; n   4;
Figure 2. Concentration dependence of the CD69 ex-
pression in BALF eosinophils after SAP. Purified BALF
eosinophils (0.5   105/ml) from asthmatics obtained 18 h
after SAP were incubated with 0.05, 0.5, 5, or 50 ng/ml
NGF, BDNF, NT-3, or NT-4, respectively, or with cell
culture medium alone (control, 0 ng/ml). After 4 h, the
CD69 expression was measured by flow cytometry. The
figure shows representative results from one of two inde-
pendent experiments.
Figure 3. Ex vivo viability of BALF eosinophils after 72 h is increased
in comparison to peripheral blood eosinophils. Peripheral blood (PB-Eos;
0.5   105) isolated 10 min before and 18 h after SAP or BALF eosino-
phils (BALF-Eos; 0.5   105/ml) isolated 18 h after SAP, respectively,
were cultured for 72 h in cell culture medium (each n   4). Percentage of
cell survival was determined by cytometry with a PI exclusion assay.
Control blood eosinophils were isolated from a separate group of unchal-
lenged healthy donors (n   9); *P   0.05.T
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P   0.05; Fig. 4). There were no significant differences in
the percentage of viable cells after stimulation with the dif-
ferent neurotrophins.
In comparison, incubation with 10 ng/ml of IL-5 pro-
longed survival of both peripheral blood and BALF eo-
sinophils in a similar order of magnitude. The observed
differences between IL-5 stimulated eosinophils and un-
stimulated control cells were statistically significant (P  
0.05) in all eosinophil preparations examined irrespec-
tively of whether cells were obtained from peripheral
blood or BALF.
The neurotrophin-mediated increase in survival of
BALF eosinophils after stimulation with NGF, BDNF,
NT-3, or NT-4 was concentration-dependent. The in-
crease in eosinophil survival after stimulation with either
NGF, BDNF, NT-3, or NT-4 was of the same order of
magnitude among the different neurotrophins (Fig. 5).
Neutralization of Neurotrophin-induced Survival and CD69
Surface Expression. Addition of neutralizing Abs against
NGF, BDNF, NT-3, or NT-4 to neurotrophin-stimulated
BALF eosinophils abrogated the neurotrophin-mediated
effect on CD69 expression (Fig. 6 A) and caused a signifi-
cant decrease in the percentage of viable BALF eosinophils
(Fig. 6 B; each n   4, P   0.05). In contrast, CD69 ex-
pression and eosinophil survival were not affected by coin-
cubation with the control mAb of the same isotype (IgG1).
Identification of Neurotrophin Receptor mRNA Expression in
Eosinophils by PCR. To identify the mechanisms by
which neurotrophins exert the observed effects on eosino-
phils, mRNA expression for neurotrophin receptors was
investigated by RT-PCR. Fig. 7 shows the expression of
mRNA for p75NTR, trkA, trkB, and trkC in BALF eo-
sinophils of asthmatics 18 h after allergen provocation. In
contrast, peripheral blood eosinophils expressed only
mRNA for trkA following SAP while the levels of expres-
sion of mRNA for p75, trkB, and trkC were below the de-
tection limit (Fig. 7).
Immunocytochemical Identification of Neurotrophin Receptors of
Eosinophils. To confirm the RT-PCR data, expression of
neurotrophin receptors was also examined by immunocy-
tochemistry. None of the cytospin preparations which
were incubated with a negative control antibody (IgG1,
IgG2a, IgG2b, or rabbit IgG, respectively) yielded positively
stained cells. There was no positive staining for either ex-
tracellular or intracellular domains of the neurotrophin re-
ceptors trkA, trkB, or trkC, nor the extracellular domain of
the p75NTR on peripheral blood eosinophils from healthy
donors or patients with asthma before SAP (data not de-
picted) nor on peripheral blood eosinophils from asthmatic
patients 18 h after SAP (n   4). However, BALF eosino-
phils from all samples investigated (n    4) expressed
p75NTR as well as the intra- and extracellular domains of
trkA, trkB, and trkC. Fig. 8 gives representative examples
of the cytochemical analysis of the extracellular domains
from the individual neurotrophin receptors.
Discussion
Inflammatory processes and responses to proinflamma-
tory mediators in vitro are potent inducers of neurotrophin
release by nerve cells (45, 46) and a wide range of haemato-
poietic cells including mast-cells (13, 14), macrophages (12,
15, 16), T cells (11, 12, 16, 32), B cells (12, 36), and NK
Figure 4. Comparison of the viability of peripheral blood eosinophils
with BALF eosinophils after stimulation with neurotrophins. Isolated
eosinophils (0.5   105/ml) of peripheral blood (PB-Eos) from healthy
subjects (A, n   6) or asthmatics 10 min before (B, n   4) and 18 h after
SAP (C, n   4) as well as BALF eosinophils collected 18 h after SAP
(BALF-Eos; D, n   4) were incubated with 50 ng/ml NGF, BDNF,
NT-3, or NT-4, respectively, or with 10 ng/ml IL-5 or cell culture me-
dium alone (control). The viability was assessed by flow cytometry with
PI immediately after isolation (0 d) and after 1, 2, and 3 d (PB-Eos from
healthy subjects) or after 3, 5, and 7 d (PB-Eos from asthmatics before and
after SAP) or after 0, 3, 5, 7, 10, and 14 d, respectively (BALF-Eos from
asthmatics); * significant differences (P   0.05).T
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cells (47). Neurotrophins have been observed in elevated
concentrations in several inflammatory conditions (48–50)
and have recently been described in allergic diseases (5, 51–
53). An up-regulation of neurotrophins was seen during
the allergic late phase response in BALF following SAP (7).
The late phase reaction in asthma following allergen provo-
Figure 5. Concentration dependence of the viability of
BALF eosinophils after stimulation with neurotrophins.
Isolated BALF eosinophils (0.5   105/ml) collected 18 h
after SAP (BALF-Eos) were incubated with 0.05, 0.5, 5, or
50 ng/ml NGF, BDNF, NT-3, or NT-4, respectively, or
cell culture medium alone (control, 0 ng/ml). The viability
was assessed by flow cytometry with PI after 10 d. The
figure shows representative results from one of two inde-
pendent experiments.
Figure 6. Neutralization of the neurotrophin-induced increase in CD69 expression and viability by mAbs against NGF, BDNF, NT-3, and NT-4.
The effects of NGF, BDNF, NT-3, and NT-4 on activation and viability of BALF eosinophils are inhibited by coincubation with neutralizing Abs
against the neurotrophins. In contrast, the coincubation with a control Ab of the same isotype caused no change in CD69 expression measured after 4 h
(A) or eosinophil survival measured after 10 d (B). Representative histograms (A) or dotplots (B) from one of four independent experiments are depicted.
The depicted numbers in each graph (B) give the percentages of the viable, PI negative eosinophils.T
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cation is dominated by an influx of activated eosinophils
into the bronchial lumen, which correlates with the release
of eosinophilic products into the airways, disease severity
and the development of BHR (3, 4). The mechanisms,
which regulate eosinophil activation, however, in vivo are
incompletely understood. In this study, we compared the
influence of the neurotrophins NGF, BDNF, NT-3, and
NT-4 on survival and activation of peripheral blood eo-
sinophils from healthy donors and from patients with mild
allergic asthma before and after SAP with those of BALF
eosinophils infiltrating the lung after allergen exposure. We
were able to show that both viability and CD69 expression
were significantly enhanced after stimulation of BALF eo-
sinophils with NGF as well as BDNF, NT-3, and NT-4,
whereas no changes in survival and induction of CD69 sur-
face expression were observed in peripheral blood eosino-
phils of patients with bronchial asthma nor in those of
healthy subjects. In contrast, IL-5 prolonged survival and
increased CD69 expression of all investigated eosinophil
preparations in a similar, nonselective manner. Addition of
neutralizing anti-neurotrophin antibodies in vitro abro-
gated the effects of neurotrophins on BALF eosinophils.
However, from our study design we cannot fully exclude
that the observed changes could be due to an indirect ac-
tion of neurotrophins, e.g., by triggering cytokine release
from eosinophils which affect eosinophil function by auto-
crine or paracrine mechanisms. On the other hand such an
action has not yet been reported and the neurotrophin-
induced up-regulation of CD69 occurred rapidly, which
would make indirect effects of neurotrophins unlikely.
NGF has previously been shown to affect the viability of
peripheral blood eosinophils from healthy donors (23, 54).
The results of these studies, however, gave conflicting re-
sults with respect to the influence of NGF on eosinophil
survival. Both authors suggested a role for NGF in the de-
velopment of allergic inflammation because NGF was
shown to induce ECP release and enhance eosinophil che-
motactic activity. The cytokine like functions of NGF have
been highlighted by several studies recently. NGF is
known to prolong the survival of murine and human neu-
trophils (55, 56) and to promote the growth and differenti-
ation of myeloid and erythroid progenitors (57, 58). NGF
influences the proliferation of both human B and T lym-
phocytes, acts as survival factor for memory B cells (59, 60),
triggers several biological functions of mature myeloid cells
as in monocytes/macrophages (32, 61), basophils (37, 62),
and mast cells (21). Although a multitude of physiological
functions for NGF have been described in the immune
system, a similar role for the structurally closely related
BDNF, NT-3, and NT-4 remained unclear, despite the
observation that receptors for these neurotrophins are ex-
pressed on the surface of various immunocompetent cells
(14, 31, 33, 34, 38).
In this study, we now provide evidence for a functional
role of BDNF, NT-3, and NT-4 on eosinophil viability
and activation. Interestingly, this effect of neurotrophins
was only observed on cells from BALF obtained from seg-
ments that had been locally challenged by allergen but not
in cells obtained from blood. As neurotrophins had no
measurable effects on peripheral blood eosinophils, the ef-
fects of neurotrophin effects appear to depend on allergen-
induced preactivation of eosinophils. This has not previ-
ously been demonstrated and underscores the requirement
to study allergic inflammation locally.
In comparison to peripheral blood eosinophils, eosino-
phils of the BALF have an increased expression of the acti-
vation markers HLA-DR and CD69, an enhanced super-
oxide production and adhere more easily to collagen and
human umbilical vein endothelial cells (HUVECs; refer-
ences 63 and 64). Based on these observation we postulate
that pulmonary eosinophils develop an increased expression
of neurotrophin specific receptors compared with periph-
eral blood eosinophils.
We therefore analyzed neurotrophin receptor expression
on peripheral blood eosinophils as well as on BALF eo-
sinophils after SAP. Both immunocytochemistry and RT-
PCR revealed that BALF eosinophils expressed all three
tyrosine kinases as well as the p75NTR. In contrast, we
observed trkA specific mRNA expression in peripheral
blood eosinophils from asthmatics after SAP, but, in agree-
ment with functional data, immunoreactivity was not ob-
served for the trks or the p75NTR in these cells. This cor-
responds with our observation of comparable changes in
viability and CD69 expression of BALF eosinophils to the
different neurotrophins tested indicating an activation-
dependent up-regulation of neurotrophin receptor expres-
sion. In contrast to our findings, neurotrophin receptor
expression was recently reported in peripheral blood eo-
Figure 7. mRNA expression of neurotrophin receptors
in eosinophils. Expression of mRNA for  -actin (positive
control, 194 bp), p75NTR (147 bp), trkA (479 bp), trkB
(221 bp), and trkC (356 bp) in peripheral blood eosino-
phils (PB-Eos) or BALF eosinophils, respectively, from
asthmatics 18 h after SAP. M, 100 bp DNA ladder; RNA,
RNA control.T
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sinophils from patients with mild eosinophilia and a history
of allergic disease (65). The data in that study are, how-
ever, inconsistent. mRNA for these receptors was reported
in about half of the allergic patients and trkA and trkC
protein were detectable by Western blot only. Laurenzi et
al. suggested that granulocytes in the peripheral blood of
healthy donors generally lacked mRNA expression for
neurotrophin receptors (39), although expression of trkB
kinase, the truncated trkC, and the trkC kinase have been
reported in mature eosinophils in human bone marrow
(38). In conclusion, there is evidence to suggest that neu-
rotrophin receptor expression is subject to local, allergen-
dependent, compartmentalized regulation in which neu-
rotrophin receptor expression might indicate eosinophil
maturation and/or (pre) activation.
Although our findings are compatible with our hypothe-
sis of an allergen-dependent up-regulation of all examined
neurotrophin receptors in eosinophils after SAP, the de-
Figure 8. Immunocytochemical detection of neu-
rotrophin receptor expression in cytospin preparations
from purified peripheral blood eosinophils and BALF
cells. In BALF cells, a strong immunoreactivity for the
extracellular proportions of trkA, trkB, trkC, and the
p75NTR was observed in eosinophils (arrows),
whereas no immunoreactivity for any of the neurotro-
phin receptors was noted in eosinophils from peripheral
blood (PB-Eos; trkA mAb from Cymbus Biotechnol-
ogy LTD, trkB pAb from Chemicon, trkC mAb from
R&D Systems, and p75NTR mAb from NeoMarkers).
None of the cytospin preparations incubated with a
negative control antibody (IgG1, IgG2a, IgG2b, or rabbit
IgG, respectively) yielded positively stained cells (de-
picted are representative photographs from cells which
were incubated with IgG1).T
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tailed mechanism by which the effects of neurotrophins are
mediated in eosinophils is at present unclear. Recent evi-
dence from an animal model of allergic asthma indicates
that p75NTR plays a critical role in the accumulation of
eosinophils in the lung: Tokuoka et al. demonstrated that
p75NTR knockout mice developed markedly diminished
allergic inflammation and no airway eosinophilia (66).
These data have been corroborated by Kerzel et al. who
showed that blocking of p75NTR by local antibody treat-
ment prevents eosinophilic lung inflammation in a murine
asthma model (67). These findings, however, do not rule
out that trks can play a critical role in eosinophil activation.
Both p75NTR and trks alone or in cooperation can medi-
ate neurotrophin signals including survival or inhibition of
apoptosis. In neurons activation of p75NTR induces the
expression of the transcription factor nuclear factor  B
(NF B; references 68 and 69). Activation of the tyrosine
kinases induces the antiapoptotic bcl-2 and activation of
phosphatidylinositol-3 kinase, the serine/threonine kinase
Akt and the MAP kinase cascade (70, 71) by which the
high affinity receptors as well as the p75NTR can mediate
a signal for survival. Our observation that the p75NTR as
well as the tyrosinkinases trkA, trkB, and trkC are ex-
pressed on the surface of BALF eosinophils is compatible
with the hypothesis that both low affinity and high affinity
NGF receptors play a critical role in eosinophilic inflamma-
tion in allergen induced asthma especially as p75NTR pro-
vides a positive modulatory influence on trk function as has
recently been described (72, 73).
In conclusion this is the first study to demonstrate aller-
gen-dependent up-regulation of the neurotrophin recep-
tors p75NTR, trkA, trkB, and trkC on eosinophils from
BALF compared with peripheral blood eosinophils. This
neurotrophin receptor expression translates into an in-
creased activation and viability of BALF eosinophils in
vitro after incubation with neurotrophins such as NGF,
BDNF, NT-3, and NT-4. Our findings suggest that neu-
rotrophin mediated activation of bronchial eosinophils
might play a role in the regulation of eosinophilic inflam-
mation in allergic asthma. The factors regulating neurotro-
phin receptor expression remain to be elucidated.
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